Home » Stocks » ARTL

Artelo Biosciences, Inc. (ARTL)

Stock Price: $1.14 USD 0.13 (12.87%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $1.13 -0.01 (-0.88%) Jan 22, 7:59 PM
Market Cap 17.91M
Revenue (ttm) n/a
Net Income (ttm) -4.78M
Shares Out 10.22M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.14
Previous Close $1.01
Change ($) 0.13
Change (%) 12.87%
Day's Open 1.03
Day's Range 1.03 - 1.19
Day's Volume 5,815,163
52-Week Range 0.46 - 2.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK

GlobeNewsWire - 2 weeks ago

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoi...

GlobeNewsWire - 1 month ago

Expanding the patent estate for the lead clinical program to treat cancer anorexia Expanding the patent estate for the lead clinical program to treat cancer anorexia

GlobeNewsWire - 1 month ago

LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modul...

GlobeNewsWire - 1 month ago

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modul...

GlobeNewsWire - 2 months ago

Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders Mitacs Accelerate grant expected to fund 50% of research costs...

GlobeNewsWire - 2 months ago

First patients on track for enrollment this year

GlobeNewsWire - 2 months ago

LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate...

GlobeNewsWire - 3 months ago

Reports positive preclinical data in animal models Reports positive preclinical data in animal models

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments int...

GlobeNewsWire - 3 months ago

LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments int...

GlobeNewsWire - 3 months ago

Barry J. A. Laird, M.D. of the University of Edinburgh’s Institute of Genetics and Molecular Medicine Appointed Coordinating Investigator Barry J. A. Laird, M.D. of the University of Edinburgh...

GlobeNewsWire - 4 months ago

LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocann...

GlobeNewsWire - 4 months ago

LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocann...

GlobeNewsWire - 6 months ago

LA JOLLA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modu...

GlobeNewsWire - 8 months ago

Claims to Improve Drug-Like Properties of CBD Receive Intellectual Property Protection Through 2038 Claims to Improve Drug-Like Properties of CBD Receive Intellectual Property Protection Throu...

GlobeNewsWire - 11 months ago

FABP5 platform under exclusive license to Artelo Biosciences

About ARTL

Artelo Biosciences, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Gregory D. Gorgas
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
ARTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ARTL stock is "Buy" and the 12-month stock price forecast is 3.00.

Price Target
$3.00
Analyst Consensus: Buy